Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women

Jon J. Ladd, Timothy Chao, Melissa M. Johnson, Ji Qiu, Alice Chin, Rebecca Israel, Sharon J. Pitteri, Jianning Mao, Mei Wu, Lynn M. Amon, Martin McIntosh, Christopher Li, Ross Prentice, Nora Disis, Samir Hanash

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We assessed the autoantibody repertoire of a mouse model engineered to develop breast cancer and the repertoire of autoantibodies in human plasmas collected at a preclinical time point and at the time of clinical diagnosis of breast cancer. In seeking to identify common pathways, networks, and protein families associated with the humoral response, we elucidated the dynamic nature of tumor antigens and autoantibody interactions. Lysate proteins from an immortalized cell line from a MMTV-neu mouse model and from MCF7 human breast cancers were spotted onto nitrocellulose microarrays and hybridized with mouse and human plasma samples, respectively. Immunoglobulin-based plasma immunoreactivity against glycolysis and spliceosome proteins was a predominant feature observed both in tumor-bearing mice and in prediagnostic human samples. Interestingly, autoantibody reactivity was more pronounced further away than closer to diagnosis. We provide evidence for dynamic changes in autoantibody reactivity with tumor development and progression that may depend, in part, on the extent of antigen-antibody interactions.

Original languageEnglish (US)
Pages (from-to)1502-1513
Number of pages12
JournalCancer Research
Volume73
Issue number5
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Glycolysis
Autoantibodies
Breast Neoplasms
Proteins
Spliceosomes
Collodion
Neoplasm Antigens
Immunoglobulins
Neoplasms
Antigens
Cell Line
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. / Ladd, Jon J.; Chao, Timothy; Johnson, Melissa M.; Qiu, Ji; Chin, Alice; Israel, Rebecca; Pitteri, Sharon J.; Mao, Jianning; Wu, Mei; Amon, Lynn M.; McIntosh, Martin; Li, Christopher; Prentice, Ross; Disis, Nora; Hanash, Samir.

In: Cancer Research, Vol. 73, No. 5, 01.03.2013, p. 1502-1513.

Research output: Contribution to journalArticle

Ladd, JJ, Chao, T, Johnson, MM, Qiu, J, Chin, A, Israel, R, Pitteri, SJ, Mao, J, Wu, M, Amon, LM, McIntosh, M, Li, C, Prentice, R, Disis, N & Hanash, S 2013, 'Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women', Cancer Research, vol. 73, no. 5, pp. 1502-1513. https://doi.org/10.1158/0008-5472.CAN-12-2560
Ladd, Jon J. ; Chao, Timothy ; Johnson, Melissa M. ; Qiu, Ji ; Chin, Alice ; Israel, Rebecca ; Pitteri, Sharon J. ; Mao, Jianning ; Wu, Mei ; Amon, Lynn M. ; McIntosh, Martin ; Li, Christopher ; Prentice, Ross ; Disis, Nora ; Hanash, Samir. / Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. In: Cancer Research. 2013 ; Vol. 73, No. 5. pp. 1502-1513.
@article{0dda4ac00eea4f7b90aa832f21730ab1,
title = "Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women",
abstract = "We assessed the autoantibody repertoire of a mouse model engineered to develop breast cancer and the repertoire of autoantibodies in human plasmas collected at a preclinical time point and at the time of clinical diagnosis of breast cancer. In seeking to identify common pathways, networks, and protein families associated with the humoral response, we elucidated the dynamic nature of tumor antigens and autoantibody interactions. Lysate proteins from an immortalized cell line from a MMTV-neu mouse model and from MCF7 human breast cancers were spotted onto nitrocellulose microarrays and hybridized with mouse and human plasma samples, respectively. Immunoglobulin-based plasma immunoreactivity against glycolysis and spliceosome proteins was a predominant feature observed both in tumor-bearing mice and in prediagnostic human samples. Interestingly, autoantibody reactivity was more pronounced further away than closer to diagnosis. We provide evidence for dynamic changes in autoantibody reactivity with tumor development and progression that may depend, in part, on the extent of antigen-antibody interactions.",
author = "Ladd, {Jon J.} and Timothy Chao and Johnson, {Melissa M.} and Ji Qiu and Alice Chin and Rebecca Israel and Pitteri, {Sharon J.} and Jianning Mao and Mei Wu and Amon, {Lynn M.} and Martin McIntosh and Christopher Li and Ross Prentice and Nora Disis and Samir Hanash",
year = "2013",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-12-2560",
language = "English (US)",
volume = "73",
pages = "1502--1513",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women

AU - Ladd, Jon J.

AU - Chao, Timothy

AU - Johnson, Melissa M.

AU - Qiu, Ji

AU - Chin, Alice

AU - Israel, Rebecca

AU - Pitteri, Sharon J.

AU - Mao, Jianning

AU - Wu, Mei

AU - Amon, Lynn M.

AU - McIntosh, Martin

AU - Li, Christopher

AU - Prentice, Ross

AU - Disis, Nora

AU - Hanash, Samir

PY - 2013/3/1

Y1 - 2013/3/1

N2 - We assessed the autoantibody repertoire of a mouse model engineered to develop breast cancer and the repertoire of autoantibodies in human plasmas collected at a preclinical time point and at the time of clinical diagnosis of breast cancer. In seeking to identify common pathways, networks, and protein families associated with the humoral response, we elucidated the dynamic nature of tumor antigens and autoantibody interactions. Lysate proteins from an immortalized cell line from a MMTV-neu mouse model and from MCF7 human breast cancers were spotted onto nitrocellulose microarrays and hybridized with mouse and human plasma samples, respectively. Immunoglobulin-based plasma immunoreactivity against glycolysis and spliceosome proteins was a predominant feature observed both in tumor-bearing mice and in prediagnostic human samples. Interestingly, autoantibody reactivity was more pronounced further away than closer to diagnosis. We provide evidence for dynamic changes in autoantibody reactivity with tumor development and progression that may depend, in part, on the extent of antigen-antibody interactions.

AB - We assessed the autoantibody repertoire of a mouse model engineered to develop breast cancer and the repertoire of autoantibodies in human plasmas collected at a preclinical time point and at the time of clinical diagnosis of breast cancer. In seeking to identify common pathways, networks, and protein families associated with the humoral response, we elucidated the dynamic nature of tumor antigens and autoantibody interactions. Lysate proteins from an immortalized cell line from a MMTV-neu mouse model and from MCF7 human breast cancers were spotted onto nitrocellulose microarrays and hybridized with mouse and human plasma samples, respectively. Immunoglobulin-based plasma immunoreactivity against glycolysis and spliceosome proteins was a predominant feature observed both in tumor-bearing mice and in prediagnostic human samples. Interestingly, autoantibody reactivity was more pronounced further away than closer to diagnosis. We provide evidence for dynamic changes in autoantibody reactivity with tumor development and progression that may depend, in part, on the extent of antigen-antibody interactions.

UR - http://www.scopus.com/inward/record.url?scp=84874845828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874845828&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-2560

DO - 10.1158/0008-5472.CAN-12-2560

M3 - Article

VL - 73

SP - 1502

EP - 1513

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -